ATE217863T1 - Arylsulfonylaminohydroxamsäurederivate - Google Patents

Arylsulfonylaminohydroxamsäurederivate

Info

Publication number
ATE217863T1
ATE217863T1 AT98305959T AT98305959T ATE217863T1 AT E217863 T1 ATE217863 T1 AT E217863T1 AT 98305959 T AT98305959 T AT 98305959T AT 98305959 T AT98305959 T AT 98305959T AT E217863 T1 ATE217863 T1 AT E217863T1
Authority
AT
Austria
Prior art keywords
aryl
acid derivatives
arylsulfonylaminohydroxamic
arylsulfonylaminohydroxamic acid
angiogenisis
Prior art date
Application number
AT98305959T
Other languages
English (en)
Inventor
Ralph Pelton Robinson
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of ATE217863T1 publication Critical patent/ATE217863T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT98305959T 1997-08-08 1998-07-27 Arylsulfonylaminohydroxamsäurederivate ATE217863T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5520897P 1997-08-08 1997-08-08

Publications (1)

Publication Number Publication Date
ATE217863T1 true ATE217863T1 (de) 2002-06-15

Family

ID=21996365

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98305959T ATE217863T1 (de) 1997-08-08 1998-07-27 Arylsulfonylaminohydroxamsäurederivate

Country Status (9)

Country Link
EP (1) EP0895988B1 (de)
JP (1) JPH11116549A (de)
AT (1) ATE217863T1 (de)
BR (1) BR9803128A (de)
CA (1) CA2244501C (de)
DE (1) DE69805473T2 (de)
DK (1) DK0895988T3 (de)
ES (1) ES2176913T3 (de)
PT (1) PT895988E (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8469601A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Procedimiento para alquilar sulfonamidas impedidas estericamente
PA8469301A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Procedimientos para la preparacion de acidos hidroxamicos.
GT199900044A (es) * 1998-04-10 2000-09-14 Procedimientos para preparar haluros de fenoxifenilsulfonilo.
AU3196300A (en) * 1999-03-26 2000-10-16 Shionogi & Co., Ltd. Carbocyclic sulfonamide derivatives
EP1041072B1 (de) * 1999-03-31 2003-07-16 Pfizer Products Inc. Dioxocyclopentylhydroxamsäure
IL138686A0 (en) 1999-10-01 2001-10-31 Pfizer Prod Inc α- SULFONYLAMINO HYDROXAMIC ACID INHIBITORS OF MATRIX METALLOPROTEINASES FOR THE TREATMENT OF PERIPHERAL OR CENTRAL NERVOUS SYSTEM DISORDERS
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
US7141607B1 (en) 2000-03-10 2006-11-28 Insite Vision Incorporated Methods and compositions for treating and inhibiting retinal neovascularization
IL151250A0 (en) 2000-03-21 2003-04-10 Procter & Gamble Difluorobutyric acid metalloprotease inhibitors
EP1265864A1 (de) * 2000-03-21 2002-12-18 The Procter & Gamble Company Heterozyklische seitenkette enhaltende, n-substituierte metalloproteaseinhibitoren
EP1208092B1 (de) * 2000-04-07 2006-06-21 Samsung Electronics Co., Ltd. Sulfonamide als matrix-metalloproteinase inhibitoren
US7067148B2 (en) 2001-02-15 2006-06-27 King Pharmaceutical Research & Development, Inc. Stabilized pharmaceutical and thyroid hormone compositions and method of preparation
ES2345977T3 (es) * 2001-03-14 2010-10-07 Novartis Ag Derivados de acido acetico azacicloalquil sustituidos para uso como inhibidores de mmp.
PH12012502440A1 (en) 2001-06-26 2013-06-17 Amgen Inc Antibodies to opgl
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
US7176217B2 (en) 2001-11-13 2007-02-13 Shiseido Co., Ltd. Azabicyclo compound matrix metalloprotease inhibitor and skin preparation
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
US7504537B2 (en) 2001-12-27 2009-03-17 Dainippon Sumitomo Pharma Co., Ltd. Hydroxamic acid derivative and MMP inhibitor containing the same as active ingredient
AU2003299971A1 (en) 2002-12-30 2004-07-29 Amgen Inc. Combination therapy with co-stimulatory factors
GB0326546D0 (en) * 2003-11-14 2003-12-17 Amersham Plc Inhibitor imaging agents
JP2007516982A (ja) 2003-12-15 2007-06-28 日本たばこ産業株式会社 シクロプロパン化合物及びその医薬用途
KR20060109937A (ko) * 2003-12-15 2006-10-23 니뽄 다바코 산교 가부시키가이샤 Ｎ-치환-ｎ-술포닐아미노시클로프로판 화합물 및 그의약제학적 용도

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10501806A (ja) * 1994-06-22 1998-02-17 ブリティッシュ バイオテック ファーマシューティカルズ リミテッド 金属タンパク質分解酵素阻害剤
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
WO1998007697A1 (en) * 1996-08-23 1998-02-26 Pfizer Inc. Arylsulfonylamino hydroxamic acid derivatives

Also Published As

Publication number Publication date
JPH11116549A (ja) 1999-04-27
EP0895988A1 (de) 1999-02-10
DE69805473T2 (de) 2003-01-16
CA2244501A1 (en) 1999-02-08
EP0895988B1 (de) 2002-05-22
CA2244501C (en) 2003-03-18
ES2176913T3 (es) 2002-12-01
DE69805473D1 (de) 2002-06-27
DK0895988T3 (da) 2002-09-09
PT895988E (pt) 2002-09-30
BR9803128A (pt) 2000-05-02

Similar Documents

Publication Publication Date Title
ATE217863T1 (de) Arylsulfonylaminohydroxamsäurederivate
EP0818442A3 (de) Cyclische Sulphonderivate als Metalloproteinase-Inhibitoren und zur Hemmung der Produktion von Tumornekrosefaktor
MY113586A (en) Aylsulfonylamino hydroxamic acid derivatives
CA2218503A1 (en) Arylsulfonyl hydroxamic acid derivatives
FR2744010B1 (fr) Procede de fabrication d'implants osseux
EA199900139A1 (ru) Производные арилсульфониламиногидроксамовой кислоты
CA2349227A1 (en) Substituted 2-phenylbenzimidazoles, the production thereof and their use
MY121754A (en) Arylsulfonylamino hydroxamic acid derivatives
ATE223215T1 (de) Inhibitoren der fettsäuresynthese als antimikrobielle mittel
ZA987087B (en) Chemical compounds
MX9804793A (es) Acidos arilsulfonamido-hidroxamicos alfa-sustituidos como inhibidores de factor de necrosis tumoral-alfa y de metaloproteinasa de matriz.
EA199900641A1 (ru) Производные арилсульфонилгидроксамовой кислоты
CA2343204A1 (en) Arylsulfonanilide ureas
WO2003007719A1 (fr) Nettoyants, systeme de nettoyage, agents de blanchiment et compositions pour la preservation de l'environnement
ATE272398T1 (de) Verwendung von ep4 rezeptorliganden zur behandlung von neuropathischen schmerz
CA2340138A1 (en) 2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases
CA2254731A1 (en) Inhibition of matrix metalloproteases by 2-substituted-4-(4-substitutedphenyl)-4-oxobutyric acids
EP1152004A4 (de) Derivate der phosphonsäure zur inhibierung von carboxypeptidase b
WO2000015208A3 (en) New use of immunosupressants for mmp-mediated diseases
DK0826681T3 (da) Epoxyravsyrederivater
CA2253796A1 (en) Inhibition of matrix metalloproteases by acetylene containing compounds
TNSN04055A1 (fr) Formes cristallines anhydres de gabapentine
AU2723192A (en) Thiadiazinone
TW363056B (en) Inhibition of matrix metalloproteases by substituted phenethyl compounds
AP2002002587A0 (en) Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee